253 related articles for article (PubMed ID: 34506119)
1. Ellagic Acid Modulates Uninduced as well as Mutation and Metal-Induced Aggregation of α-Synuclein: Implications for Parkinson's Disease.
Meena VK; Kumar V; Karalia S; Garima ; Sundd M
ACS Chem Neurosci; 2021 Oct; 12(19):3598-3614. PubMed ID: 34506119
[TBL] [Abstract][Full Text] [Related]
2. Ellagic Acid Inhibits α-Synuclein Aggregation at Multiple Stages and Reduces Its Cytotoxicity.
Kumar S; Kumar R; Kumari M; Kumari R; Saha S; Bhavesh NS; Maiti TK
ACS Chem Neurosci; 2021 Jun; 12(11):1919-1930. PubMed ID: 34015214
[TBL] [Abstract][Full Text] [Related]
3. NMR unveils an N-terminal interaction interface on acetylated-α-synuclein monomers for recruitment to fibrils.
Yang X; Wang B; Hoop CL; Williams JK; Baum J
Proc Natl Acad Sci U S A; 2021 May; 118(18):. PubMed ID: 33903234
[TBL] [Abstract][Full Text] [Related]
4. Library-Derived Peptide Aggregation Modulators of Parkinson's Disease Early-Onset α-Synuclein Variants.
Watt KJC; Meade RM; Williams RJ; Mason JM
ACS Chem Neurosci; 2022 Jun; 13(12):1790-1804. PubMed ID: 35613323
[TBL] [Abstract][Full Text] [Related]
5. Ellagic Acid Prevents α-Synuclein Aggregation and Protects SH-SY5Y Cells from Aggregated α-Synuclein-Induced Toxicity via Suppression of Apoptosis and Activation of Autophagy.
Ardah MT; Eid N; Kitada T; Haque ME
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948195
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the in vivo induction and transmission of α-synuclein pathology by mutant α-synuclein fibril seeds in transgenic mice.
Rutherford NJ; Dhillon JS; Riffe CJ; Howard JK; Brooks M; Giasson BI
Hum Mol Genet; 2017 Dec; 26(24):4906-4915. PubMed ID: 29036344
[TBL] [Abstract][Full Text] [Related]
7. Unravelling the destabilization potential of ellagic acid on α-synuclein fibrils using molecular dynamics simulations.
Mankoo OK; Kaur A; Goyal D; Goyal B
Phys Chem Chem Phys; 2023 Mar; 25(11):8128-8143. PubMed ID: 36877087
[TBL] [Abstract][Full Text] [Related]
8. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.
Rutherford NJ; Moore BD; Golde TE; Giasson BI
J Neurochem; 2014 Dec; 131(6):859-67. PubMed ID: 24984882
[TBL] [Abstract][Full Text] [Related]
9. The effect of truncation on prion-like properties of α-synuclein.
Terada M; Suzuki G; Nonaka T; Kametani F; Tamaoka A; Hasegawa M
J Biol Chem; 2018 Sep; 293(36):13910-13920. PubMed ID: 30030380
[TBL] [Abstract][Full Text] [Related]
10. Structures of the E46K mutant-type α-synuclein protein and impact of E46K mutation on the structures of the wild-type α-synuclein protein.
Wise-Scira O; Dunn A; Aloglu AK; Sakallioglu IT; Coskuner O
ACS Chem Neurosci; 2013 Mar; 4(3):498-508. PubMed ID: 23374074
[TBL] [Abstract][Full Text] [Related]
11. The loss of inhibitory C-terminal conformations in disease associated P123H β-synuclein.
Janowska MK; Baum J
Protein Sci; 2016 Jan; 25(1):286-94. PubMed ID: 26332674
[TBL] [Abstract][Full Text] [Related]
12. Structures and free energy landscapes of the A53T mutant-type α-synuclein protein and impact of A53T mutation on the structures of the wild-type α-synuclein protein with dynamics.
Coskuner O; Wise-Scira O
ACS Chem Neurosci; 2013 Jul; 4(7):1101-13. PubMed ID: 23607785
[TBL] [Abstract][Full Text] [Related]
13. Familial Parkinson disease mutations influence α-synuclein assembly.
Ono K; Ikeda T; Takasaki J; Yamada M
Neurobiol Dis; 2011 Sep; 43(3):715-24. PubMed ID: 21684335
[TBL] [Abstract][Full Text] [Related]
14. Structural and mechanistic insights into modulation of α-Synuclein fibril formation by aloin and emodin.
Meena VK; Kumar V; Karalia S; Dangi RS; Sundd M
Biochim Biophys Acta Gen Subj; 2022 Jul; 1866(7):130151. PubMed ID: 35421539
[TBL] [Abstract][Full Text] [Related]
15. Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy.
Bodner CR; Maltsev AS; Dobson CM; Bax A
Biochemistry; 2010 Feb; 49(5):862-71. PubMed ID: 20041693
[TBL] [Abstract][Full Text] [Related]
16. Scutellarin inhibits the uninduced and metal-induced aggregation of α-Synuclein and disaggregates preformed fibrils: implications for Parkinson's disease.
Zaidi FK; Deep S
Biochem J; 2020 Feb; 477(3):645-670. PubMed ID: 31939603
[TBL] [Abstract][Full Text] [Related]
17. Alpha-synuclein stepwise aggregation reveals features of an early onset mutation in Parkinson's disease.
de Oliveira GAP; Silva JL
Commun Biol; 2019; 2():374. PubMed ID: 31633065
[TBL] [Abstract][Full Text] [Related]
18. Unveiling a Selective Mechanism for the Inhibition of α-Synuclein Aggregation by β-Synuclein.
Leitao A; Bhumkar A; Hunter DJB; Gambin Y; Sierecki E
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364143
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of alpha-synuclein aggregation by AM17, a synthetic resveratrol derivative.
Chau E; Kim H; Shin J; Martinez A; Kim JR
Biochem Biophys Res Commun; 2021 Oct; 574():85-90. PubMed ID: 34454326
[TBL] [Abstract][Full Text] [Related]
20. Loss in Toxic Function of Aggregates of α -Synuclein Mutants by a β-Synuclein Derived Peptide.
Mohammadi S; Nikkhah M; Hosseinkhani S
Protein Pept Lett; 2017; 24(8):757-764. PubMed ID: 28820063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
